PathAI logo

Targeted Solid Tumor Sequencing Panel

Next Generation Sequencing (NGS) · Dermatology
The Targeted Solid Tumor Sequencing Panel utilizes the Illumina TruSight Tumor 15 (TST15) assay which is a targeted cancer gene panel dedicated to detecting variants by covering the implicated coding regions of 15 genes associated with solid tumors. TST15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of the most commonly mutated genes in 7 cancer types (Lung, Melanoma, Breast, Colon, Ovarian, Gastric, and Prostate). It detects low-frequency variants down to a 5% minor allele frequency (MAF) and requires only 20 ng of DNA isolated from FFPE tumor tissue. TST15 allows for parallel sequencing of multiple cancer-related genes without the need to perform several sequential tests.